GILEAD SCIENCES, INC. is 58.4x more valuable than Relay Therapeutics, Inc. by market capitalization ($150.83 B vs $2.58 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RLAY | GILD |
|---|---|---|
| Market cap | $2.58 B | $150.83 B |
| US-listed rank | #1916 | #99 |
| Revenue (latest FY) | $15.36M | $29.44B |
| Net income (latest FY) | -$276.48M | $8.51B |
| Net margin | -1800.6% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 506 | 981 |
GILEAD SCIENCES, INC. is 58.4x more valuable than Relay Therapeutics, Inc. by market capitalization ($150.83 B vs $2.58 B).
In their latest fiscal years, Relay Therapeutics, Inc. reported $15.36M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Relay Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.